The solid showing comes less than two weeks after the Beverly, Mass.-based pharmaceutical company reported favorable results in a recently completed preclinical study evaluating its new antibiotic compounds against specific strains of multi-drug resistant Klebsiella pneumoniae.
http://ift.tt/1hJwl3D
http://ift.tt/1hJwl3D
No comments:
Post a Comment